Myovant Sciences Ltd. | Business Contracts

Letter Agreement by and between Myovant Sciences GmbH and Pfizer, Inc. dated September 19, 2022 (Filed With SEC on October 26, 2022)

Amendment No. 4 to Market Access Services Agreement by and between Sunovion Pharmaceuticals Inc. and Myovant Sciences GmbH, dated August 9, 2022 (Filed With SEC on October 26, 2022)

Agreement and Plan of Merger, dated as of October 23, 2022, among Myovant Sciences Ltd., Sumitovant Biopharma Ltd., Merger Sub and, solely with respect to Article IX and Annex A,... (Filed With SEC on October 24, 2022)

Non-Executive Director Compensation Policy (Filed With SEC on May 11, 2022)

Amendment No. 4 to License Agreement (Filed With SEC on May 11, 2022)

Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement under 2020 Inducement Plan (Non-U.S. Form) (Filed With SEC on May 11, 2021)

Amendment No. 3 to Market Access Services Agreement by and between Sunovion Pharmaceuticals Inc. and Myovant Sciences GmbH, dated March 15, 2021 (Filed With SEC on October 26, 2022)

Amended and Restated Manufacturing & Services Agreement by and between Excella GmbH & Co. KG and Myovant Sciences GmbH, dated April 2, 2021 (Filed With SEC on October 26, 2022)

Voting and Support Agreement, dated as of October 23, 2022, between Myovant Sciences Ltd. and Sumitovant Biopharma Ltd (Filed With SEC on October 24, 2022)

Letter of Understanding between Myovant Sciences, Inc. and Matthew Lang (Filed With SEC on July 27, 2022)

Amendment No.1 to Myovant Sciences Ltd. 2020 Inducement Plan (Filed With SEC on March 25, 2022)

Employment Agreement, dated as of August 12, 2021, by and between Uneek Mehra and Myovant Sciences, Inc (Filed With SEC on October 26, 2021)

Letter Agreement, dated July 27, 2021, by and between Myovant Sciences GmbH and Pfizer, Inc (Filed With SEC on October 26, 2021)

Separation Agreement and General Release, dated as of August 11, 2021, by and between Frank Karbe and Myovant Sciences, Inc (Filed With SEC on October 26, 2021)

Letter Agreement (Filed With SEC on July 28, 2021)

Commercial Manufacturing & Supply Agreement, effective as of May 30, 2018, by and between Myovant Sciences GmbH and Takeda Pharmaceutical Company Limited (Filed With SEC on May 11, 2021)

Non-Employee Director Compensation Policy (Filed With SEC on May 11, 2021)

Form of 2021 Incentive Bonus Letter with Executive Officers (Filed With SEC on May 11, 2021)

Form of Restricted Stock Unit Grant Notice and Award Agreement under 2016 Equity Incentive Plan, as amended (2019 Non-U.S. Form) (Filed With SEC on May 11, 2021)

Employment Agreement, effective as of April 5, 2021, by and between Lauren Merendino and Myovant Sciences, Inc (Filed With SEC on May 11, 2021)

Separation Agreement (Filed With SEC on May 11, 2021)

Employment Agreement, dated as of January 4, 2021, by and between David Marek and Myovant Sciences, Inc (Filed With SEC on May 11, 2021)

Amendment No.2 to Market Access Services Agreement, dated as of January 25, 2021, by and between Sunovion Pharmaceuticals Inc. and Myovant Sciences GmbH (Filed With SEC on May 11, 2021)

Amendment No.1 to Market Access Services Agreement, dated as of (Filed With SEC on February 11, 2021)

Amendment No. 3 to License Agreement, dated December 15, 2020, by and between the Registrant and Takeda Pharmaceuticals International AG (Filed With SEC on February 11, 2021)

Amendment to Consulting Agreement, dated November 11, 2020, by and between the Registrant and Sumitovant BioPharma, Inc (Filed With SEC on February 11, 2021)

Commitment Letter Amendment Letter, dated December 22, 2020, by and between Sumitomo Dainippon Pharma Co., Ltd. and the Registrant (Filed With SEC on February 11, 2021)

Market Access Services Agreement, dated as of August 1, 2020, by and between Sunovion Pharmaceuticals Inc. and Myovant Sciences GmbH (Filed With SEC on November 12, 2020)

Form of Restricted Stock Unit Grant Notice and (Filed With SEC on November 12, 2020)

Form of Option Grant Notice and Option Agreement under 2020 Inducement Plan (Filed With SEC on November 12, 2020)

2020 Inducement Plan (Filed With SEC on November 12, 2020)

Commitment Letter Amendment Letter (Filed With SEC on November 12, 2020)

Commitment Letter, dated August 5, 2020, by and between Sumitomo Dainippon Pharma Co., Ltd. and the Registrant (Filed With SEC on November 12, 2020)

Commercial Manufacturing and Supply Agreement, dated April 4, 2019, by and between Excella GmbH & Co. KG and Myovant Sciences GmbH (Filed With SEC on November 12, 2020)

Consulting Agreement, dated May 18, 2020, by and between the Registrant and Sumitovant BioPharma Ltd (Filed With SEC on August 11, 2020)

Description of Common Shares (Filed With SEC on May 18, 2020)

Investor Rights Agreement, dated as of December 27, 2019, by and among the Registrant, Sumitovant Biopharma Ltd. and Sumitomo Dainippon Pharma Co., Ltd (Filed With SEC on February 10, 2020)

Loan Agreement, dated as of December 27, 2019, by and among Sumitomo Dainippon Pharma Co., Ltd., as the Lender, the Registrant, as the Parent, and Myovant Sciences GmbH, as the... (Filed With SEC on February 10, 2020)

Letter Agreement, dated October 31, 2019, by and between the Registrant and Sumitomo Dainippon Pharma Co., Ltd (Filed With SEC on February 10, 2020)

Form of Restricted Stock Unit Grant Notice and Award Agreement under 2016 Equity Incentive Plan, as amended (2019 Form) (Filed With SEC on November 12, 2019)

Form of Amendment No.1 to the Stock Option Grant Notice and Option Agreement under 2016 Equity Incentive Plan, as amended (Filed With SEC on November 12, 2019)

Underwriting Agreement, by and between Myovant Sciences Ltd. and J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC, Cowen and Company, LLC, and Evercore Group L.L.C., as... (Filed With SEC on May 31, 2019)

Form of Restricted Stock Unit Grant Notice and Award Agreement under 2016 Equity Incentive Plan, as amended (Filed With SEC on May 24, 2019)

Restricted Stock Award Agreement, dated May 31, 2017, by and between Myovant Sciences Ltd. and Lynn Seely (Filed With SEC on May 24, 2019)

Amendment No.1 to Information Sharing and Cooperation Agreement, dated as of May 24, 2019, by and between Roivant Sciences Ltd. and the Registrant (Filed With SEC on May 24, 2019)

Form of Restricted Stock Award Agreement under 2016 Equity Incentive Plan, as amended (Filed With SEC on May 24, 2019)

Non-Employee Director Compensation Policy (Filed With SEC on May 24, 2019)

Employment Agreement, dated as of November 1, 2018, by and between Kim Sablich and Myovant Sciences, Inc (Filed With SEC on February 7, 2019)

Myovant Sciences Ltd. (48)